Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Published byΚαλυψώ Μέλιοι Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile."— Presentation transcript:

1 Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study.58 P2Y12 reaction units in clopidogrel-nonresponsive patients before and after crossover. Patients treated with ticagrelor in period 1 received a 600 mg clopidogrel loading dose followed by 75 mg daily maintenance therapy in period 2; patients treated with clopidogrel in period 1 received a 180 mg ticagrelor loading dose followed by 90 mg twice-daily maintenance therapy in period 2. *P < ‡P <0.05. Reprinted from Gurbel, P. A. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (10), 1188–1199 (2010), with permission from Wolters Kluwer Health and the American Heart Association. Reprinted from Gurbel, P. A. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (10), 1188–1199 (2010), with permission from Wolters Kluwer Health and the American Heart Association Rollini, F. et al. (2015) Switching P2Y12-receptor inhibitors in patients with coronary artery disease Nat. Rev. Cardiol. doi: /nrcardio

Download ppt "Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile."

Similar presentations

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with.

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.
Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97:38-43. Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impaired Responsiveness to the Platelet P2Y 12 Receptor.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impaired Responsiveness to the Platelet P2Y 12 Receptor.
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI

Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Metabolism pathway of antiplatelet agents

Figure 3 Metabolism pathway of antiplatelet agents
Figure 2 Different manifestations of myocardial ischaemia

Figure 2 Different manifestations of myocardial ischaemia
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Figure 2 Binding properties of P2Y12-receptor inhibitors

Figure 2 Binding properties of P2Y12-receptor inhibitors
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 5 BMI and cardiorespiratory fitness levels

Figure 5 BMI and cardiorespiratory fitness levels
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 4 Pharmacodynamic comparison of crushed versus integral
Figure 4 BMI and mortality in patients with heart failure

Figure 4 BMI and mortality in patients with heart failure
Figure 1 Energy supply–demand matching in health and heart failure

Figure 1 Energy supply–demand matching in health and heart failure

Similar presentations

Ads by Google